Employees: 1,066
Size Mingyue Optical Lens (301101.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.07B, the 2029th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥36.04 on 18 Nov 2026.
Performance Over six months the shares fell 4.5%, against -8.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 14.5% over the last twelve months (peer median +10.0%); the operating margin is 25.3% (peer median 11.8%).
Valuation It trades at 31.6× forward earnings against a peer median of 18.4× (3rd most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 29.1 points above its cost of capital (6.8% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥931M | CN¥821M | CN¥764M | CN¥742M | CN¥617M |
| Revenue growth | — | +8% | +3% | +20% | — |
| Gross profit | CN¥562M | CN¥445M | CN¥422M | CN¥410M | CN¥316M |
| EBITDA | n/a | CN¥264M | CN¥239M | CN¥218M | CN¥165M |
| Net income | CN¥220M | CN¥193M | CN¥177M | CN¥158M | CN¥136M |
| Free cash flow | CN¥179M | CN¥207M | CN¥179M | CN¥155M | CN¥95.0M |
| Capital expenditure | CN¥93.2M | CN¥96.8M | CN¥70.8M | CN¥81.4M | CN¥77.5M |
| Total debt | CN¥2.53M | CN¥49.5M | CN¥4.01M | CN¥6.81M | CN¥9.57M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301101.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +17.7% | -6.0% | highest of 21 |
| 6-month return | -4.5% | -8.9% | 9th highest of 20 |
| Distance from 52-week high | -27.8% | -29.0% | 11th highest of 21 |
| Revenue growth (TTM) | +14.5% | +10.0% | 6th highest of 19 |
| Operating margin | 25.3% | 11.8% | 8th highest of 20 |
| Forward P/E | 31.6× | 18.4× | 3rd most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 8.8% | 6.9% | 6th most demanding of 14 |
| Growth delivered (Del g) | +8.8% | +10.4% | 6th lowest of 14 |
| Hurdle (Req g minus delivered) | +0.0 pp | -3.0 pp | 6th most demanding of 14 |
| ROIC minus cost of capital | +29.1 pp | +1.5 pp | 3rd highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |